D. Zembryki

发表

Oral Versus Intravenous Administration of Vinorelbine as a Single Agent for the First-Line Treatment of Metastatic Nonsmall Cell Lung Carcinoma (NSCLC): A Randomized Phase II Trial

J. Rigas, L. Nguyen, V. Hirsh, 2007, American journal of clinical oncology.

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases

R. Greil, E. Winer, N. Lin, 2011, Journal of Neuro-Oncology.

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER 2-Positive Breast Cancer

R. Greil, E. Winer, Minetta C. Liu, 2009 .

Differential inhibition of histamine release from mast cells by protein kinase C inhibitors: staurosporine and K-252a.

J. White, D. Zembryki, N. Hanna, 1990, Biochemical pharmacology.

Absence of the OKT4 epitope on blood T cells and thymus cells in a patient with thymoma, hypogammaglobulinemia, and red blood cell aplasia.

J. Hoxie, A. Levinson, D. Zembryki, 1985, The Journal of allergy and clinical immunology.

Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.

K. Erhard, R. Keenan, M. Lark, 1999, Bioorganic & medicinal chemistry letters.

Development and Characterization of a Human In Vitro Resorption Assay: Demonstration of Utility Using Novel Antiresorptive Agents

M. Lark, I. James, T. Tomaszek, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Potent and Selective Cathepsin L Inhibitors Do Not Inhibit Human Osteoclast Resorption in Vitro *

Y. Ru, D. Veber, D. Yamashita, 2001, The Journal of Biological Chemistry.

Phenotypic and functional analysis of B cell lines from patients with multiple myeloma.

J. Hoxie, A. Levinson, D. Zembryki, 1985, Blood.

Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.

Baoguang Zhao, M. Head, D. Veber, 2006, Journal of medicinal chemistry.

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

R. Greil, E. Winer, Minetta C. Liu, 2009, Clinical Cancer Research.

Phenotypic and functional analysis of B cell lines from patients with multiple myeloma

J. Hoxie, A. Levinson, D. Zembryki, 1985 .

EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT)

E. Winer, V. Diéras, C. Oliva, 2007 .

An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.

S. Johnston, G. Jerusalem, P. Conte, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU)

J. Baselga, M. Casey, V. Diéras, 2008 .

Design of potent and selective human cathepsin K inhibitors that span the active site.

J G Gleason, S. Carr, R. DesJarlais, 1997, Proceedings of the National Academy of Sciences of the United States of America.

(2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6- pentamethylpiperidin-4-yl)-2,4-pentadienamide, a novel, potent and selective inhibitor of the osteoclast V-ATPase.

C. Parini, S. Gagliardi, D. Zembryki, 1998, Bioorganic & medicinal chemistry letters.

Differentiation of second messenger systems in mast cell activation

J. White, D. Zembryki, 1989, Agents and Actions.

Cardiac safety of the lapatinib/letrozole combination as first-line therapy in patients (pts) with metastatic breast cancer (MBC).

H. Gómez, M. Koehler, S. Johnston, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.